133 related articles for article (PubMed ID: 14728852)
21. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
[TBL] [Abstract][Full Text] [Related]
22. Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment.
Picchio M; Sironi S; Messa C; Mangili G; Landoni C; Gianolli L; Zangheri B; Viganò R; Aletti G; De Marzi P; De Cobelli F; Del Maschio A; Ferrari A; Fazio F
Q J Nucl Med; 2003 Jun; 47(2):77-84. PubMed ID: 12865867
[TBL] [Abstract][Full Text] [Related]
23. [Metabolic characterization of ovarian tumors with positron-emission tomography and F-18 fluorodeoxyglucose].
Römer W; Avril N; Dose J; Ziegler S; Kuhn W; Herz M; Jänicke F; Schwaiger M
Rofo; 1997 Jan; 166(1):62-8. PubMed ID: 9072107
[TBL] [Abstract][Full Text] [Related]
24. Combined FDG-positron emission tomography and computed tomography for the detection of ovarian cancer recurrence in an inguinal hernia sac.
Díaz-Montes TP; Jacene HA; Wahl RL; Bristow RE
Gynecol Oncol; 2005 Sep; 98(3):510-2. PubMed ID: 15992914
[TBL] [Abstract][Full Text] [Related]
25. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection.
Even-Sapir E; Parag Y; Lerman H; Gutman M; Levine C; Rabau M; Figer A; Metser U
Radiology; 2004 Sep; 232(3):815-22. PubMed ID: 15273334
[TBL] [Abstract][Full Text] [Related]
26. Positron emission tomography in the management of documented or suspected recurrent ovarian cancer.
Chou HH; Chen CY; Liu FY; Lin G; Wang CC; Yang LY; Chen MY; Pan YB; Wu RC; Yen TC; Chang TC; Lai CH
J Formos Med Assoc; 2017 Nov; 116(11):869-879. PubMed ID: 28089190
[TBL] [Abstract][Full Text] [Related]
27. Role of PET/CT in ovarian cancer.
Prakash P; Cronin CG; Blake MA
AJR Am J Roentgenol; 2010 Jun; 194(6):W464-70. PubMed ID: 20489063
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study.
Langenhoff BS; Oyen WJ; Jager GJ; Strijk SP; Wobbes T; Corstens FH; Ruers TJ
J Clin Oncol; 2002 Nov; 20(22):4453-8. PubMed ID: 12431968
[TBL] [Abstract][Full Text] [Related]
29. Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma.
Karlan BY; Hawkins R; Hoh C; Lee M; Tse N; Cane P; Glaspy J
Gynecol Oncol; 1993 Nov; 51(2):175-81. PubMed ID: 8276290
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.
Sanli Y; Turkmen C; Bakir B; Iyibozkurt C; Ozel S; Has D; Yilmaz E; Topuz S; Yavuz E; Unal SN; Mudun A
Nucl Med Commun; 2012 May; 33(5):509-15. PubMed ID: 22357440
[TBL] [Abstract][Full Text] [Related]
31. PET-CT in recurrent ovarian cancer: impact on treatment planning.
Lenhard MS; Burges A; Johnson TR; Stieber P; Kümper C; Ditsch N; Linke R; Friese K
Anticancer Res; 2008; 28(4C):2303-8. PubMed ID: 18751410
[TBL] [Abstract][Full Text] [Related]
32. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer.
Nakamoto Y; Saga T; Ishimori T; Mamede M; Togashi K; Higuchi T; Mandai M; Fujii S; Sakahara H; Konishi J
AJR Am J Roentgenol; 2001 Jun; 176(6):1449-54. PubMed ID: 11373212
[TBL] [Abstract][Full Text] [Related]
33. Benefits of fluorine-18 fludeoxyglucose positron emission tomography in secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer.
Peng P; Zhu ZH; Zhong ZJ; Zheng K; Yang JX; Cao DY; Shen K
Br J Radiol; 2015 Aug; 88(1052):20150109. PubMed ID: 25989698
[TBL] [Abstract][Full Text] [Related]
34. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.
Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H
Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962
[TBL] [Abstract][Full Text] [Related]
35. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
[TBL] [Abstract][Full Text] [Related]
36. [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma.
Kim S; Chung JK; Kang SB; Kim MH; Jeong JM; Lee DS; Lee MC
Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):196-201. PubMed ID: 15129701
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET.
Kahn D; Follett KA; Bushnell DL; Nathan MA; Piper JG; Madsen M; Kirchner PT
AJR Am J Roentgenol; 1994 Dec; 163(6):1459-65. PubMed ID: 7992747
[TBL] [Abstract][Full Text] [Related]
38. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy.
Eubank WB; Mankoff DA; Schmiedl UP; Winter TC; Fisher ER; Olshen AB; Graham MM; Eary JF
AJR Am J Roentgenol; 1998 Oct; 171(4):1103-10. PubMed ID: 9763005
[TBL] [Abstract][Full Text] [Related]
39. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.
Sun SS; Chen TC; Yen RF; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(4B):2957-61. PubMed ID: 11712793
[TBL] [Abstract][Full Text] [Related]
40. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
